Get the Stockscreener App
7.28
0.97%
0.07
Xeris Biopharma Holdings Inc stock is traded at $7.28, with a volume of 2.81M.
It is up +0.97% in the last 24 hours and up +6.59% over the past month.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
See More
Previous Close:
$7.21
Open:
$7.17
24h Volume:
2.81M
Relative Volume:
1.20
Market Cap:
$1.21B
Revenue:
$246.03M
Net Income/Loss:
$-32.00M
P/E Ratio:
-34.26
EPS:
-0.2125
Net Cash Flow:
$-16.78M
1W Performance:
+2.54%
1M Performance:
+6.59%
6M Performance:
+56.90%
1Y Performance:
+112.87%
1-Day Range:
$7.01
$7.395
1-Week Range:
$6.97
$7.445
52-Week Range:
$3.14
$10.08
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Name
Xeris Biopharma Holdings Inc
Sector
Industry
Phone
844-445-5704
Address
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
7.28 | 1.20B | 246.03M | -32.00M | -16.78M | -0.2125 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.21 | 116.79B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.17 | 81.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.70 | 53.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
845.95 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.77 | 37.48B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Overweight |
| Aug-12-25 | Resumed | H.C. Wainwright | Buy |
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Aug-28-23 | Initiated | Craig Hallum | Buy |
| Oct-21-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Craig Hallum | Buy |
| Nov-17-21 | Initiated | SVB Leerink | Outperform |
| Oct-29-21 | Initiated | H.C. Wainwright | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-18-20 | Initiated | Piper Sandler | Overweight |
| Jul-16-18 | Initiated | Jefferies | Buy |
| Jul-16-18 | Initiated | Leerink Partners | Outperform |
| Jul-16-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Xeris Biopharma Holdings Inc Stock (XERS) Latest News
Have Xeris Biopharma Holdings Insiders Been Selling Stock? - Sahm
Will Xeris Biopharma Holdings Inc. stock pay special dividendsStop Loss & Target Return Focused Stock Picks - Улправда
Will Xeris Biopharma Holdings Inc. stock benefit from sector rotationJuly 2025 Technicals & High Accuracy Buy Signal Tips - Улправда
Squarepoint Ops LLC Purchases 268,572 Shares of Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Xeris Biopharma (XERS): Assessing Valuation as Investors Back Its Shift to Profitable Specialty Pharma - Sahm
EBIT per share of Xeris Biopharma Holdings, Inc. – LSE:0A8E - TradingView — Track All Markets
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Director John Johnson Sells 135,400 Shares of Xeris Biopharma Ho - GuruFocus
Xeris Biopharma (NASDAQ:XERS) Director Sells $977,588.00 in Stock - MarketBeat
Xeris Biopharma Holdings Insider Sold Shares Worth $977,019, According to a Recent SEC Filing - marketscreener.com
Will Xeris Biopharma Holdings Inc. stock reach all time highs in 20252025 Investor Takeaways & Free Long-Term Investment Growth Plans - DonanımHaber
How Xeris Biopharma’s Shift Toward Profitability and Pipeline Maturity Will Impact Xeris (XERS) Investors - Sahm
Is Xeris Biopharma Holdings Inc. stock a contrarian buyJuly 2025 Selloffs & Safe Entry Point Alerts - Улправда
Xeris Biopharma Holdings, Inc. (XERS): A Bull Case Theory - Finviz
Xeris Biopharma: A Balanced Perspective Needed (Rating Downgrade) - Seeking Alpha
Insider Selling: Xeris Biopharma (NASDAQ:XERS) Director Sells 15,000 Shares of Stock - MarketBeat
Insider Sell: Barbara-jean Bormann-kennedy Sells 15,000 Shares o - GuruFocus
Xeris Biopharma (XERS) director reports 15,000-share stock sale - Stock Titan
Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue? - MSN
Walleye Capital LLC Sells 448,444 Shares of Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Jump Financial LLC Raises Stock Position in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
561,700 Shares in Xeris Biopharma Holdings, Inc. $XERS Bought by Norges Bank - MarketBeat
Xeris Biopharma (NASDAQ:XERS) Coverage Initiated at Barclays - MarketBeat
Barclays Initiates Coverage on Xeris Biopharma Holdings (XERS) w - GuruFocus
Barclays Initiates Xeris Biopharma Holdings at Overweight With $9 Price Target - marketscreener.com
Xeris Biopharma (XERS): Valuation Check After USPTO Notice of Allowance for Weekly Levothyroxine XP-8121 Patent - Sahm
Xeris Biopharma’s (XERS) Positioning Strengthens After Reaching Product Pipeline Milestone - Insider Monkey
7 Hidden Multibagger Stocks to Invest In - Insider Monkey
Xeris Biopharma Holdings (XERS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Xeris Biopharma (XERS) Is Down 9.3% After XP-8121 Patent Milestone Is Announced – Has The Bull Case Changed? - Yahoo Finance
Is Xeris Biopharma (XERS) Using XP-8121 Patents to Quietly Redefine Its Long-Term Growth Story? - Sahm
How Xeris Biopharma Holdings Inc. stock performs in weak economy2025 Price Momentum & Verified Trade Idea Suggestions - Newser
Why Xeris Biopharma Holdings Inc. (2B30) stock is favored by hedge funds2025 Momentum Check & Fast Gain Stock Tips - Newser
What Wall Street predicts for Xeris Biopharma Holdings Inc. stock price2025 Major Catalysts & Verified High Yield Trade Plans - Newser
How higher bond yields impact Xeris Biopharma Holdings Inc. (2B30) stockJuly 2025 Opening Moves & Community Verified Watchlist Alerts - Newser
Xeris Biopharma (NASDAQ:XERS) Insider Sells $116,835.67 in Stock - MarketBeat
Xeris Biopharma (NASDAQ:XERS) Shares Down 4.9%Here's Why - MarketBeat
What Analysts Think Is Changing The Story For Xeris Biopharma Holdings - Yahoo Finance
What is Xeris Biopharma Holdings Inc (XERS) Stock Return on Shareholders’ Capital? - Setenews
Risks Still Elevated At These Prices As Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Dive 35% - simplywall.st
Legal & General Group Plc Purchases 392,589 Shares of Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Is Xeris Biopharma Holdings Inc. stock a safe buy before earningsEarnings Growth Summary & Safe Capital Growth Plans - Newser
Why Xeris Biopharma Holdings Inc. (2B30) stock appeals to dividend investorsMarket Risk Analysis & Growth Focused Entry Reports - Newser
Hecht Beth, Xeris Biopharma chief legal officer, sells $116k in XERS - Investing.com India
Hecht Beth, Xeris Biopharma chief legal officer, sells $116k in XERS By Investing.com - Investing.com South Africa
Xeris Biopharma Holdings Director Beth Hecht Sells Shares - TradingView
Officer Hecht Sells 16,667 ($116.8K) Of Xeris Biopharma Holdings Inc [XERS] - TradingView
Oversold Conditions For Xeris Biopharma Holdings (XERS) - Nasdaq
Why Xeris Biopharma Holdings Inc. (2B30) stock is listed among top recommendations2025 Institutional Moves & Daily Stock Momentum Reports - Newser
A Look at Xeris Biopharma (XERS) Valuation After Patent Progress on Novel Hypothyroidism Therapy - Sahm
Xeris Pharmaceuticals Secures Patent Allowance for XP-8121 - MSN
Xeris Biopharma Holdings Inc Stock (XERS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.36%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):